[1]孙建军** 陈素华 尹晓亮 陈新 杨辰龙 于涛 马千权 杨军** 常青① 田素青② 马长城 韩芸峰 刘颖③ 吴超.侧方非功能区入路切除功能区脑胶质瘤[J].中国微创外科杂志,2021,01(2):112-116.
　Sun Jianjun,Chen Suhua,Yin Xiaoliang,et al.Lateral Nonfunctional Area Approaches for Resection Glioma Under Brain Functional Cortex[J].Chinese Journal of Minimally Invasive Surgery,2021,01(2):112-116.
点击复制

侧方非功能区入路切除功能区脑胶质瘤()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2021年2期
页码:
112-116
栏目:
临床研究
出版日期:
2021-02-25

文章信息/Info

Title:
Lateral Nonfunctional Area Approaches for Resection Glioma Under Brain Functional Cortex
作者:
孙建军** 陈素华 尹晓亮 陈新 杨辰龙 于涛 马千权 杨军** 常青① 田素青② 马长城 韩芸峰 刘颖③ 吴超
（北京大学第三医院神经外科北京大学医学部精准神经外科与肿瘤研究中心，北京100191）
Author(s):
Sun Jianjun;  Chen Suhua;  Yin Xiaoliang;  et al.
Department of Neurosurgery, Peking University Third Hospital, Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Beijing 100191,China
关键词:
脑胶质瘤; 功能区; 侧方非功能区入路
Keywords:
Brain gliomas; Functional area; Lateral nonfunctional approaches
文献标志码:
A
摘要:
目的探讨侧方非功能区入路切除功能区脑胶质瘤的安全性。方法2018年8月~2019年12月对36例功能区脑胶质瘤行侧方避开功能区皮层的手术入路，导航、显微镜下黄荧光指引下切除脑内胶质瘤，入路包括利用脑叶旁间隙、附近非功能区脑沟回和功能区皮层侧方进入3种方式。应用格拉斯哥预后评分（Glasgow Outcome Scale,GOS)评估术后神经功能状况。结果肿瘤全切除26例(722%），近全切除4例(11.1%)，次全切5例(13.9%)，大部切除1例(2.8%)。术后肢体肌力较术前改善10例（27.8%），言语功能较术前改善5例（13.9%）。GOS评分5分30例，4分6例。36例随访4~20个月,平均11个月。偏瘫进一步恢复3例，失语进一步恢复2例，癫痫继续发作2例，肿瘤复发8例（首次术后6~8个月复发，复发后再次手术4例）。3例分别于首次手术后11、12、18个月发生继发中线播散。1例原发性胶质母细胞瘤未能进行有效的放化疗，术后11个月死亡，且6-氧-甲基鸟嘌呤-DNA-甲基转移酶阴性，异柠檬酸脱氢酶-1（isocitrate dehydrogenase 1, IDH1）野生型。结论侧方非功能区入路切除功能区脑胶质瘤安全可行、微创，值得推广。
Abstract:
ObjectiveTo analyze the safety of lateral nonfunctional area approaches for resection the glioma under brain functional cortex.MethodsFrom August 2018 to December 2019, 36 patients were presented and suffered with glioma under brain functional cortex. Lateral nonfunctional area approaches were performed in all the 36 patients, assisted with neuronavigation and yellow flourescence. Lateral nonfunctional area approaches included three types: natural space beside the functional lobuscerebris,adjoined nonfunctional cerebral cortex, and lateral functional cerebral cortex. The Glasgow Outcome Scale(GOS) was used to judge the postoperative nervous functional state of patients.ResultsGross total resection was performed in 26 (72.2%) cases under microscope, nearly total resection in 4 (11.1%) cases, subtotal resection in 5 (13.9%) cases, and partial resection in 1(2.8%) case. The muscle strength of limbs was improved in 10 (27.8%) cases, and speech function was improved in 5 (13.9%) cases after operation. Five points of GOS were gotten in 30 (83.3%) cases, and four points in 6 (16.7%) cases. All the 36 patients were followed up for 4-20 months (mean, 11 months). Hemiparalysis was improved in 3 cases, and speech function was improved in 2 cases. Epilepsy was reserved in 2 cases. Glioma recurred in 8 cases (from 6 to 8 months after first operation), and 4 cases accepted a second open surgery. The secondary midline spread occurred in 3 cases at 11, 12 and 18 months respectively after the first operation. One patient with primary glioblastoma failed to receive effective radiotherapy and chemotherapy, and died at 11 months after operation, whose genetic testing result was O6methylguanineDNA methyltransferase（MGMT) negative and isocitrate dehydrogenase 1(IDH1) wild type.ConclusionLateral nonfunctional area approaches are safe, minimally invasive and feasible for resection the glioma under brain functional area.

参考文献/References:

[1]Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol, 2014,16(7):896-913.
[2]Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol,2018,51:50-58.
[3]Ostrom QT, Gittleman H, Stetson L, et al. Epidemiology of gliomas. Cancer Treat Res,2015,163(51):1-14.
[4]Ma Q, Long W, Xing C, et al. Cancer stem cells and immunosuppressive microenvironment in glioma. Front Immunol,2018,9:2924.
[5]Thomas TM, Yu JS. Metabolic regulation of glioma stemlike cells in the tumor microenvironment. Cancer Lett,2017,408:174-181.
[6]Jhaveri N, Chen TC, Hofman FM. Tumor vasculature and glioma stem cells: Contributions to glioma progression. Cancer Lett,2016,380(2):545-551.
[7]Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol,2017,134(3):505-512.
[8]Van den Bent MJ, Klein M, Smits M, et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade Ⅱ and Ⅲ glioma, without 1p/19q codeletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol,2018,19(9):1170-1179.
[9]EckelPassow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med,2015,372(26):2499-2508.
[10]Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev,2017,40(1):1-14.
[11]Feuvret L, Antoni D, Biau J, et al. Guidelines for the radiotherapy of gliomas. Cancer Radiother,2016,20(Suppl):S69-S79.
[12]Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol,2018,15(7):422-442.
[13]Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumortreating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA,2015, 314(23):2535-2543.
[14]Glenn CA, Baker CM, Conner AK, et al. An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg,2018,114:e747-e755.
[15]白少聪, 陈晓雷,耿杰峰,等.高场强术中磁共振成像及神经导航在累及视放射的颞叶胶质瘤手术中的应用.中华外科杂志,2015,53(5):340-344.
[16]张忠,江涛,谢坚,等.唤醒麻醉和术中功能定位切除语言区胶质瘤.中华神经外科杂志,2007，23（9):643-645.
[17]张岩,王硕,卓彦,等.功能磁共振与神经导航融合定位和保护脑功能应用研究.中华医学杂志,2008,88(1):2-6.
[18]于洮,赵继宗,张岩,等.神经外科术前主要汉语功能区偏侧化的功能磁共振研究.中华医学杂志,2019,99(5):329-332.
[19]Pan SY, Chen JP, Cheng WY, et al. The role of tailored intraoperative neurophysiological monitoring in glioma surgery: a single institute experience. J Neurooncol,2020,146(3):459-467.
[20]Yamaguchi F, Ten H, Higuchi T, et al. An intraoperative motor tract positioning method in brain tumor surgery: technical note. J Neurosurg,2018,129(3):576-582.
[21]Kawaguchi T, Sonoda Y, Shibahara I, et al. Impact of gross total resection in patients with WHO grade Ⅲ glioma harboring the IDH 1/2 mutation without the 1p/19q codeletion. J Neurooncol,2016, 129(3):505-514.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81872051）**通讯作者，Email：sunjianjun@bjmu.edu.cn（孙建军），13901291211@163.com（杨军）①病理科 ②肿瘤放疗科 ③放射科
更新日期/Last Update: 2021-05-11